WO2007071448A3 - Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation - Google Patents

Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation Download PDF

Info

Publication number
WO2007071448A3
WO2007071448A3 PCT/EP2006/012501 EP2006012501W WO2007071448A3 WO 2007071448 A3 WO2007071448 A3 WO 2007071448A3 EP 2006012501 W EP2006012501 W EP 2006012501W WO 2007071448 A3 WO2007071448 A3 WO 2007071448A3
Authority
WO
WIPO (PCT)
Prior art keywords
inducers
inhibitors
muscle relaxation
synthetic peptides
neurotransmitter secretion
Prior art date
Application number
PCT/EP2006/012501
Other languages
French (fr)
Other versions
WO2007071448A2 (en
Inventor
Nicolas Fasel
Amal Kuendig
Original Assignee
Partnership & Corp Technology
Nicolas Fasel
Amal Kuendig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partnership & Corp Technology, Nicolas Fasel, Amal Kuendig filed Critical Partnership & Corp Technology
Priority to US12/158,775 priority Critical patent/US8318898B2/en
Priority to MX2008008233A priority patent/MX2008008233A/en
Priority to CA002634824A priority patent/CA2634824A1/en
Priority to EP06847000A priority patent/EP1976869A2/en
Priority to BRPI0620414-7A priority patent/BRPI0620414A2/en
Publication of WO2007071448A2 publication Critical patent/WO2007071448A2/en
Publication of WO2007071448A3 publication Critical patent/WO2007071448A3/en
Priority to US13/685,114 priority patent/US20130323187A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Abstract

The present invention describes materials and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.
PCT/EP2006/012501 2005-12-23 2006-12-22 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation WO2007071448A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/158,775 US8318898B2 (en) 2005-12-23 2006-12-22 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
MX2008008233A MX2008008233A (en) 2005-12-23 2006-12-22 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation.
CA002634824A CA2634824A1 (en) 2005-12-23 2006-12-22 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
EP06847000A EP1976869A2 (en) 2005-12-23 2006-12-22 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
BRPI0620414-7A BRPI0620414A2 (en) 2005-12-23 2006-12-22 Synthetic Peptides for Use as Neurotransmitter Secretion Inhibitors and as Cellular Relaxation Inducers
US13/685,114 US20130323187A1 (en) 2005-12-23 2012-11-26 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75360705P 2005-12-23 2005-12-23
US60/753,607 2005-12-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/685,114 Continuation US20130323187A1 (en) 2005-12-23 2012-11-26 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation

Publications (2)

Publication Number Publication Date
WO2007071448A2 WO2007071448A2 (en) 2007-06-28
WO2007071448A3 true WO2007071448A3 (en) 2007-11-22

Family

ID=38123675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/012501 WO2007071448A2 (en) 2005-12-23 2006-12-22 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation

Country Status (9)

Country Link
US (2) US8318898B2 (en)
EP (2) EP1976869A2 (en)
CN (2) CN101374860A (en)
BR (1) BRPI0620414A2 (en)
CA (1) CA2634824A1 (en)
MX (1) MX2008008233A (en)
SG (1) SG163525A1 (en)
TW (1) TWI392517B (en)
WO (1) WO2007071448A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
JP5292304B2 (en) * 2006-12-01 2013-09-18 アンテリオス， インコーポレイテッド Peptide nanoparticles and uses thereof
US20100093639A1 (en) * 2006-12-29 2010-04-15 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
JP2008284318A (en) * 2007-05-15 2008-11-27 Kosumedei Seiyaku Kk Microneedle for dosing, including living body origin matter
ES2356883B1 (en) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
KR102006036B1 (en) * 2011-05-24 2019-07-31 시믹 아이피, 엘엘씨 Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
CA2888805C (en) 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
WO2013070808A1 (en) * 2011-11-07 2013-05-16 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (en) 2011-11-23 2021-11-29 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
WO2013156064A1 (en) * 2012-04-17 2013-10-24 Activen Anti-wrinkles cosmetic composition comprising a mu-conopeptide
US9566227B2 (en) 2012-04-13 2017-02-14 Activen Cosmetic composition comprising a muconopeptide
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2016535770A (en) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． Inclusion body for transdermal delivery of therapeutic and cosmetic substances
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
WO2016149637A1 (en) * 2015-03-19 2016-09-22 Kansas State University Research Foundation Nanoplatforms for arginase, indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase detection by posttranslational modification
WO2016210226A1 (en) 2015-06-26 2016-12-29 Stc.Unm Coenzyme q10 aerosol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (en) 2016-04-01 2019-01-29 Therapeuticsmd Inc pharmaceutical composition of steroid hormone
CN106546673A (en) * 2016-10-20 2017-03-29 吉尔生化（上海）有限公司 A kind of method that utilization high performance liquid chromatography separates palmityl Wushengtai 3
JP7362113B2 (en) * 2017-06-28 2023-10-17 エルジー ハウスホールド アンド ヘルスケア リミテッド Cosmetic composition for skin improvement containing a fusion protein bound to a peptide for promoting skin permeation
EP3648774A4 (en) 2017-07-07 2021-04-21 Symic IP, LLC Synthetic bioconjugates
CN107469065B (en) * 2017-07-19 2021-05-18 广州医科大学 Application of snake venom-like three-peptide in preparation of medicine for treating skin ulcer
KR102124036B1 (en) * 2018-09-18 2020-06-19 한국생산기술연구원 A expression cassette for preparation of argireline and use thereof
WO2020060202A1 (en) * 2018-09-18 2020-03-26 한국생산기술연구원 Expression cassette for preparing thymulin or argireline, and use thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN111620928B (en) * 2020-06-01 2023-02-28 陕西慧康生物科技有限责任公司 Large-scale synthesis method of hexapeptide
WO2021251789A1 (en) * 2020-06-12 2021-12-16 (주)케어젠 Composition comprising pentapeptide as active ingredient
KR102584000B1 (en) 2021-01-19 2023-10-06 김기연 Sport lotion composition comprising neurotransmitter regulating peptide
CN114835780B (en) * 2022-06-29 2022-09-27 中国农业大学 Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
EP1180524A1 (en) * 1999-04-23 2002-02-20 Lipotec, S.A. Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
US20050281816A1 (en) * 2002-10-11 2005-12-22 Norbert Lamping Modular antigen transporter molecules (MAT molecules) for modulating immune reactions, associated constructs, methods and uses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) * 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
DE69332197T2 (en) 1992-03-13 2003-04-17 Organon Teknika Bv Epstein-Barr virus related peptides and nucleic acid segments
EP0845043B1 (en) 1995-07-28 2007-06-27 Marie Curie Cancer Care Transport proteins and their uses
JPH10298196A (en) * 1997-04-28 1998-11-10 Nippon Fine Chem Co Ltd Cosmetic
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
WO1999055899A1 (en) * 1998-04-28 1999-11-04 Washington University Methods for transducing fusion molecules
CN1322129A (en) * 1998-09-01 2001-11-14 伊迪亚股份公司 Electrically controlled transport of charged penetrants across barriers
FR2783169B1 (en) 1998-09-15 2001-11-02 Sederma Sa COSMETIC OR DERMOPHARMACEUTICAL USE OF PEPTIDES FOR HEALING AND FOR IMPROVING THE SKIN APPEARANCE DURING NATURAL OR ACCELERATED AGING (HELIODERMIA, POLLUTION)
FR2784028B1 (en) * 1998-10-01 2003-02-07 Oreal USE OF A PEPTIDE FOR PREVENTING SKIN INTOLERANCE REACTIONS, ESPECIALLY IN COSMETIC COMPOSITIONS
WO2000069897A2 (en) * 1999-05-14 2000-11-23 Arbor Vita Corporation Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6794362B1 (en) * 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
WO2002018572A2 (en) * 2000-08-25 2002-03-07 Aventis Pharmaceuticals Inc Membrane penetrating peptides and uses thereof
DE10051120A1 (en) * 2000-10-14 2002-04-25 Raymond A & Cie Device for retaining and/or fixing of flat objects, especially ribbon cable for motor vehicle bodywork parts, includes base plate from which extend two elastically splayed extensions, the ends of which are joined via a three-part web
DK1342462T3 (en) 2000-11-22 2007-08-06 Otsuka Pharma Co Ltd Oil / water emulsion composition and process for preparation thereof
US7635681B2 (en) 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6821524B2 (en) 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
PL1877099T3 (en) * 2005-04-06 2013-02-28 Genzyme Corp Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
EP1180524A1 (en) * 1999-04-23 2002-02-20 Lipotec, S.A. Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
US20050281816A1 (en) * 2002-10-11 2005-12-22 Norbert Lamping Modular antigen transporter molecules (MAT molecules) for modulating immune reactions, associated constructs, methods and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIETZ G P H ET AL: "Delivery of bioactive molecules into the cell: the Trojan horse approach", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 27, no. 2, 1 October 2004 (2004-10-01), pages 85 - 131, XP004599335, ISSN: 1044-7431 *
LUPO MARY P: "Cosmeceutical peptides.", DERMATOLOGIC SURGERY : OFFICIAL PUBLICATION FOR AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY [ET AL.] JUL 2005, vol. 31, no. 7 Pt 2, July 2005 (2005-07-01), pages 832 - 836 ; dis, XP002438372, ISSN: 1076-0512 *

Also Published As

Publication number Publication date
US20130323187A1 (en) 2013-12-05
US20090226387A1 (en) 2009-09-10
TW200731997A (en) 2007-09-01
EP1976869A2 (en) 2008-10-08
BRPI0620414A2 (en) 2014-04-29
CN102408470A (en) 2012-04-11
TWI392517B (en) 2013-04-11
MX2008008233A (en) 2009-03-27
CN101374860A (en) 2009-02-25
CA2634824A1 (en) 2007-06-28
WO2007071448A2 (en) 2007-06-28
SG163525A1 (en) 2010-08-30
US8318898B2 (en) 2012-11-27
EP2172210A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
WO2007071448A3 (en) Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
MX2009008104A (en) Hepcidin, hepcidin antagonists and methods of use.
HK1123294A1 (en) Pyrazolopyrimidine derivatives for use as kinase antagonists
PT2200436E (en) Substituted pyrimidinyl-amines as protein kinase inhibitors
HK1129890A1 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2011047087A3 (en) Protein detection via nanoreporters
BRPI0813216A2 (en) PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEM.
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
PL2193133T3 (en) Imidazolothiadiazoles for use as protein kinase inhibitors
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
PL1874770T3 (en) Phenylacetamides suitable as protein kinase inhibitors
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
MX2010004219A (en) Cd19 binding agents and uses thereof.
DE602008006293D1 (en) System for reducing the wear of joint surface implants
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2008144522A8 (en) Tissue securing and sealing apparatus and related methods of use
WO2007073497A3 (en) Calcium channel antagonists
BRPI0816784A2 (en) Neuroendocrine factors for the treatment of degenerative diseases
EP2133342A4 (en) Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof
WO2007075852A3 (en) Calcium channel antagonists
GEP20125586B (en) Novel method for synthesis of (7-methoxy-l-naphthyl)-acetonitrile and application thereof in synthesis of agomelatine
HK1208701A1 (en) Means for inhibiting the expression of protein kinase
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2634824

Country of ref document: CA

Ref document number: MX/A/2008/008233

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3845/CHENP/2008

Country of ref document: IN

Ref document number: 2006847000

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200680052996.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12158775

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0620414

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080623